Paraneoplastic neurological syndromes (PNS) are a group of rarely observed disorders, accompanying about 1% of cancer diseases.
A

INTRodUCTIoN
Paraneoplastic neurological syndromes (PNS) are a group of rare disorders, associated with ca. 1% of cancers [8] . They have a typically aggressive course, leading to profound and essentially irreversible disability. Based on the current body of knowledge, the cause behind PNS is damage of the nervous system structures, resulting from the immunological reaction induced by cancer. As a result of the body's humoral response, onconeural antibodies are generated, targeting both the tumour as well as the healthy elements of nervous tissue recognized as antigens.
As a consequence of cellular reaction triggered by cytokines, the blood-brain barrier is reduced, and the nervous system is penetrated by immunocompetent cells. Presence of antineural antibodies reveals a 50-60% sensitivity and 100% specificity in diagnosing paraneoplastic neurological syndromes. In around one third of PNS patients, however, their presence is not revealed, and in one fifth of the patients, no neoplasm is observed despite the diagnosis of PNS with antibodies present [1, 5] .
Imaging and laboratory tests are of limited use in the diagnostics of PNS, with the diagnosis chiefly based on clinical symptoms assessed in accordance with the 2004 Graus's criteria [1, 4, 6, 7] .
In the course of breast cancer, the most frequently observed syndromes include the subacute cerebellar degeneration, stiff person syndrome, opsoclonus-myoclonus syndrome, paraneoplastic retinopathy, and acute necrotizing myopathy [3, 9] .
CASe PReSeNTATIoN
Patient JP-S, aged 43, was admitted to the Neurology Clinic in In April 2012, the patient's neurological condition deteriorated.
There were painful episodes of paraesthesia, and hyperaesthesia involving both lower extremities. In May 2012, the patient was hospitalized at the Department of Anaesthesiology and Intensive Care, where attempts were made to treat her with plasmapheresis, but no neurological improvement was accomplished.
The patient was discharged from hospital with persisting lower limb paraparesis (Lovett's grade 3), "knee highs" sensory disturbances, lack of stretch reflexes, and nystagmus. Definite PNS has to meet the following criteria: 1. A "classical" syndrome and cancer that develops within 5 years of the diagnosis of the neurological disorder.
2. A "non-classical" PNS that accompanies a diagnosed neoplastic disease, which resolves or significantly improves after cancer treatment without concomitant immunotherapy. PNS is a rare diagnosis (involving around 1% of neoplastic diseases), but in some cancers they are reported significantly more frequently. In the course of breast cancer, the literature has reported cases of subacute cerebellar degeneration, stiff person syndrome (SPS), opsoclonus-myoclonus syndrome, paraneoplastic retinopathy, and acute necrotizing myopathy [3, 9] . SPS is one of the non-classical paraneoplastic syndromes, and is also associated with conditions whose aetiology is other than neoplastic [1, 2, 10] . The primary symptoms of SPS include deep muscular rigidity in the region of the spine and extremities, and paroxysmal painful muscle spasms, triggered by sudden movement, noise, and emotional stress. In the majority of cases the pathogenic background is an autoimmune reactions involving the production of anti-glutamic acid decarboxylase antibodies (anti-GAD) [1, 2, 9, 10] . Anti-GAD antibodies are also observed in the course of metabolic diseases, and diabetes in particular.
SPS has also been reported as accompanying breast cancer and small-cell lung carcinoma. Apart from the anti-GAD antibodies, the syndrome also involves anti-amphiphysin antibodies, i.e. antibodies against the protein present in nerve endings, whose function is connected with the endocytosis process. 
